a public good project by the
Synthesis
Company
of California

© 2026

Homologous recombination deficiency and ovarian cancer | doi.page

0 citations0 references

Google Scholar doi.org

Homologous recombination deficiency and ovarian cancer

European Journal of Cancer·2016·Vol. 60, pp. 49–58

Citations Over TimeTop 10% of 2016 papers

Jonathan A. Ledermann, Yvette Drew, Rebecca Kristeleit

Related Papers

→ Phase I study of oral BKM120 and oral olaparib for high-grade serous ovarian cancer (HGSC) or triple-negative breast cancer (TNBC).(2014)36 cited
→ Abstract CT008: Phase I study of the alpha specific PI3-Kinase inhibitor BYL719 and the poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib in recurrent ovarian and breast cancer: Analysis of the dose escalation and ovarian cancer expansion cohort(2017)5 cited
→ High-Grade Carcinomas, BRCA Mutations and the Role of PARP Inhibitors(2016)
→ Clinical trial protocol1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer(2023)
→ Clinical trial protocol1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer(2023)